Wall Street analysts will be watching closely when ChemoCentryx, Inc. (NASDAQ:CCXI) reports its quarterly earnings next, which is scheduled for Fri 8 Mar (In 24 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at -$0.31 per share. In the preceding quarter, the company reportedly generated EPS of -$0.22 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of 11.50%, a profit margin of 13.90% and a gross margin of .
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of ChemoCentryx, Inc. (NASDAQ:CCXI). Most recently, on February 11th, 2019, Piper Jaffray Initiated a Overweight rating. Before that, on September 7th, 2018, B. Riley FBR Initiated to Neutral. JP Morgan Downgrade a Neutral rating on August 14th, 2018, Raymond James Initiated an Strong Buy rating on June 28th, 2018, and H.C. Wainwright Initiated a Buy rating on May 2nd, 2018.
At its current price point, combined with the fact that this company has 49.28M shares outstanding, the current market capitalization sits at 538.14M. In the last trading day, 3,601,078 shares of ChemoCentryx, Inc. were traded, which compares to its usual volume of about 264.20K shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by -$0.83 in the past five trading days, resulting in a percentage change of -7.06% and a moving average of 11.31. In the past 20 days, its price changed by -$1.22 (which is -10.05%) and the stock’s moving average was 11.85. Looking back a full 50 days, shares of CCXI changed by $0.62 (which is +6.02%) and demonstrated a moving average of 11.16.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 28.57%, a 14-day Stochastic %K score of 29.62% and a 20-day Stochastic %K score of 29.19%. Using a similar metric, ChemoCentryx, Inc. (CCXI) shares showed a Stochastic %D of 24.56% over the past 9 days, a Stochastic %D score of 28.50% over the last 14 days, and a 20-day Stochastic %D of 28.19%. Meanwhile, this stock’s MACD Oscillator was -0.33 over the past 9 days, -0.43 over the past two weeks, and -0.55 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $10.92 level. Over the past 12 months, this stock has experienced a high price of $15.08 and a low of $8.73. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
BVF Partners LP sold more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from ChemoCentryx, Inc. (NASDAQ:CCXI) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 6,773,760 shares of the company’s stock following the subtraction of -260,586 to this investor’s holdings during the three-month period. This share count represents that BVF Partners LP now held 13.41% stake in ChemoCentryx, Inc. (CCXI)’s shares.
Just in the most recent trading day, ChemoCentryx, Inc. (NASDAQ:CCXI) experienced a high price of $11.9 and low point of $10.56. At the end of the last trading session, this stock was at 10.92 per share, following a gain of $0.07, or -6.35% during the full day.